Welcome to repatha.co.uk/patient

This site is designed to provide patients who have been prescribed Repatha®▼ (evolocumab) with information about the treatment and other useful materials. Should you have any concerns or questions regarding your treatment with Repatha®, speak to your doctor or nurse.

Repatha®▼ (evolocumab) is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.yellowcard.co.uk. Side effects can also be reported to Amgen Limited on 01223 436441. By reporting side effects you can help provide more information on the safety of this medicine.

Why am I being prescribed Repatha®?


Repatha® is a medicine that lowers levels of ‘bad’ cholesterol, a type of fat, in the blood.

Repatha® contains the active substance evolocumab, a monoclonal antibody (a type of specialised protein designed to attach to a target substance in the body).

Evolocumab is designed to attach to a substance called PCSK9 that affects the liver’s ability to take in cholesterol. By attaching to, and mopping up PCSK9, the medicine increases the amount of cholesterol entering the liver and so lowers the level of cholesterol in the blood.


Repatha® is used in patients who cannot control their cholesterol levels with oral cholesterol drugs and/or a cholesterol lowering diet. You should stay on your cholesterol-lowering diet while taking this medicine.

Repatha® may be used with other medicines that lower your levels of cholesterol.

Repatha® can help prevent heart attack, stroke, and certain heart procedures to restore blood flow to the heart due to a build-up of fatty deposits in your arteries (also known as atherosclerotic cardiovascular disease).


Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. Repatha® is given as an injection under the skin (subcutaneous).

The recommended dose for adults with primary hypercholesterolaemia, mixed dyslipidaemia or established atherosclerotic cardiovascular disease is 140mg every two weeks.

For adults or adolescents with homozygous familial hypercholesterolaemia the recommended starting dose is 420mg once monthly. After 12 weeks your doctor may decide to increase the dose to 420mg every two weeks. If you also receive apheresis, your doctor may decide to start you on a dose of 420mg every two weeks to coincide with your apheresis treatment.

If you use more Repatha® than you should, contact your doctor or pharmacist immediately.

  1. Repatha® Summary of Product Characteristics